ACADIA Pharmaceuticals Stock Falls 6.5% After Negative EMA Vote on DAYBUE

ACADIA Pharmaceuticals shares declined by 6.5% following a negative trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The vote pertains to the Marketing Authorization Application for DAYBUE, a treatment designed for Rett syndrome. This regulatory setback in the European market contrasts with the drug's existing approval by the FDA in the United States. Investors reacted to the potential loss of international revenue growth as the path to commercialization in Europe becomes more uncertain. In response to the decision, ACADIA announced its intention to seek a formal re-examination of the application. The outcome of this regulatory hurdle is critical for the company's expansion strategy outside the North American market.